Biogen Inc (BIIB)
236.18
-0.45 -0.19%
NASDAQ
Sep 16, 12:14
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 14.07B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 26.88 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 5.294B |
| Profitability | |
| Gross Profit Margin (Quarterly) | 86.83% |
| Profit Margin (Quarterly) | 41.31% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 43.56B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 3.313 |
| PE Ratio (TTM) | 8.786 |
| Price to Book Value | 3.363 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | 1.777B |
| Return on Equity (TTM) | Upgrade |
View All BIIB News
News
-
WireHeadlineTime (ET)
-
PR Newswire09/16 11:30
-
Yahoo09/16 10:17
-
Yahoo09/16 10:16
-
Yahoo09/14 06:31
-
Yahoo09/13 11:00
-
Yahoo09/13 10:05
-
MT Newswires09/13 08:51
-
Yahoo09/13 08:44
-
Yahoo09/13 08:42
-
Yahoo09/13 08:18
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 10/23/2019 08:00 EDT | Misc | Biogen Inc Third Quarter Earnings Conference Call in 2019 |
| 10/23/2019 | Earnings | Biogen Inc Third Quarter Earnings in 2019 Release |
| 07/23/2019 08:00 EDT | Misc | Biogen Inc Second Quarter Earnings Conference Call in 2019 |
| 07/23/2019 | Earnings | Biogen Inc Second Quarter Earnings in 2019 Release |
| 06/19/2019 09:00 EDT | Misc | Biogen Inc Annual General Meeting in 2018 |
| 04/24/2019 | Earnings | Biogen Inc First Quarter Earnings Results in 2019 |
| 04/24/2019 08:00 EDT | Misc | Biogen Inc First Quarter Earnings Conference Call in 2019 |
| 02/06/2019 | Misc | Biogen Inc Annual Report in 2018 |
| 01/29/2019 08:00 EST | Misc | Biogen Inc Fourth Quarter Earnings Conference Call in 2018 |
| 01/29/2019 | Earnings | Biogen Inc Fourth Quarter Earnings Results in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.biogen.com
- Investor Relations URL: https://www.biogen.com/en_us/investors.html
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Equity Style: Large Cap/Value
- Next Earnings Release: Oct. 23, 2019
- Last Earnings Release: Jul. 23, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 236.18 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| LMPFX | ClearBridge Aggressive Growth FI | 6.72% |
| PFPWX | Parnassus Endeavor Institutional | 5.46% |
| PFPWX | Parnassus Endeavor Institutional | 5.46% |
| IBB | iShares Nasdaq Biotechnology ETF | 4.10% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.59% |
| VPMCX | Vanguard PRIMECAP Inv | 3.34% |
| VHCOX | Vanguard Capital Opportunity Inv | 2.95% |
| FXH | First Trust Health Care AlphaDEX® ETF | 2.32% |
| VPCCX | Vanguard PRIMECAP Core Inv | 1.79% |
| XBI | SPDR® S&P Biotech ETF | 1.50% |
| VGHCX | Vanguard Health Care Inv | 1.45% |
| XLV | Health Care Select Sector SPDR® ETF | 1.34% |
| VHT | Vanguard Health Care ETF | 1.15% |
Excel Add-In Codes
- Name: =YCI("BIIB","name")
- Description: =YCI("BIIB","description")
- Sector: =YCI("BIIB","sector")
- Industry: =YCI("BIIB","industry")
- Est. Current Fiscal Year End: =YCI("BIIB","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BIIB Tweets Stocktwits
Advertisement
